文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

RPE65介导遗传性视网膜营养不良儿科患者接受voretigene neparvovec基因治疗后的12个月结局

12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy.
PubMed 文献 · Br J Ophthalmol · 2025-01-28

回顾性分析6例(12眼)年龄<17岁、确诊双等位基因RPE65介导遗传性视网膜营养不良、接受视网膜下注射voretigene neparvovec(Luxturna)的儿科患者资料。12个月随访时最佳矫正视力(BCVA)显著改善(平均LogMAR 1.0±0.8 vs 0.6±0.3,p=0.001),黄斑中心厚度、中心外核层厚度及视野V4e等视线未见显著变化;术后并发症包括同一患者双眼眼压升高、治疗后3个月旁中心凹板层裂孔及注射部位萎缩(除1眼外所有眼均出现,12个月内显著扩大,p=0.008)。结论认为多数患儿12个月随访时视觉功能显著提高,且术后并发症均未阻碍视觉功能获益。

要点

  • 6例(12眼)RPE65相关遗传性视网膜营养不良儿科患者接受voretigene neparvovec视网膜下注射。
  • 12个月时平均LogMAR BCVA由基线1.0±0.8改善至0.6±0.3(p=0.001)。
  • 注射部位萎缩除1眼外所有眼均出现,12个月内显著扩大(p=0.008)。

核心结论

  • 多数接受voretigene neparvovec治疗的儿科患者在12个月随访时视觉功能显著提高。
  • 术后并发症均未阻碍视觉功能的获益。

研究设计与样本

  • 回顾性审查年龄小于17岁、确诊双等位基因RPE65介导遗传性视网膜营养不良并接受视网膜下注射voretigene neparvovec治疗的儿科患者记录。
  • 共分析6例患者的12眼,平均年龄7.8岁。
  • 在12个月随访时分析最佳矫正视力(BCVA)、谱域光学相干断层扫描、超广角眼底成像和Goldmann视野数据。

主要发现

  • 平均LogMAR BCVA由基线1.0±0.8改善至12个月时的0.6±0.3(p=0.001)。
  • 12个月随访时平均黄斑中心厚度和中心外核层厚度未见变化。
  • Goldmann视野V4e等视线未见显著变化。
  • 术后并发症包括同一患者双眼眼压升高、治疗后3个月出现旁中心凹板层裂孔及注射部位萎缩(除1眼外所有眼均出现),注射部位萎缩在12个月内显著扩大(p=0.008)。
  • 术中未发生并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To report main outcomes and complications following voretigene neparvovec (Luxturna) treatment in paediatric patients. METHODS: Records of patients under the age of 17 treated by subretinal administration of voretigene neparvovec for confirmed biallelic RPE65-mediated inherited retinal dystrophy were retrospectively reviewed. Best-corrected visual acuity (BCVA) and data from spectral-domain optical coherence tomography, ultra-wide-field fundus imaging and Goldmann visual field (VF) were analysed at 12 months follow-up. RESULTS: 12 eyes of six patients (mean age: 7.8 years) were analysed. No intraoperative complications occurred. BCVA significantly improved at 12-month follow-up (mean LogMAR (logarithm of the minimal angle of resolution) BCVA: 1.0±0.8 at baseline vs 0.6±0.3 at 12 months, p=0.001). Mean central macular thickness and central outer nuclear layer thickness did not change at 12 months follow-up. VF V4e isopter did not show significant changes. Postoperatively complications included: elevated intraocular pressure in two eyes of the same patient, a parafoveal lamellar hole at 3 months post-treatment and atrophy on the injection site observed in all eyes except one, which significantly enlarged during 12 months (p=0.008). CONCLUSIONS: Most paediatric patients treated by voretigene neparvovec showed a significant increase in visual function at 12 months follow-up. None of the postoperative complications prevented gains in visual function.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Daruich A, Rateaux M, Batté E, et al. 12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy. Br J Ophthalmol. 2025. PMID: 39578019. doi:10.1136/bjo-2024-326221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。